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Abstract Despite similar morphological aspects, ana-
plastic oligodendroglial tumors (AOTs) form a heteroge-
neous clinical subgroup of gliomas. The chromosome arms
1p/19q codeletion has been shown to be a relevant bio-
marker in AOTs and to be perfectly exclusive from EGFR
amplification in gliomas. To identify new genomic regions
associated with prognosis, 60 AOTs from the EORTC trial
26951 were analyzed retrospectively using BAC-array-
based comparative genomic hybridization. The data were
processed using a binary tree method. Thirty-three BACs
with prognostic value were identified distinguishing four
genomic subgroups of AOTs with different prognosis
(p \ 0.0001). Type I tumors (25%) were characterized by:
(1) an EGFR amplification, (2) a poor prognosis, (3) a
higher rate of necrosis, and (4) an older age of patients.
Type II tumors (21.7%) had: (1) loss of prognostic BACs
located on 1p tightly associated with 19q deletion, (2) a
longer survival, (3) an oligodendroglioma phenotype, and
(4) a frontal location in brain. Type III AOTs (11.7%)
exhibited: (1) a deletion of prognostic BACs located on
21q, and (2) a short survival. Finally, type IV tumors
(41.7%) had different genomic patterns and prognosis than
type I, II and III AOTs. Multivariate analysis showed that
genomic type provides additional prognostic data to clini-
cal, imaging and pathological features. Similar results were
obtained in the cohort of 45 centrally reviewed–validated
cases of AOTs. Whole genome analysis appears useful to
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screen the numerous genomic abnormalities observed in
AOTs and to propose new biomarkers particularly in the
non-1p/19q codeleted AOTs.
Keywords Fluorescent in situ hybridization (FISH) 
BAC-array based comparative genomic hybridization
(aCGH)  Chromosome  Prognosis  Anaplastic
Oligodendroglioma
Introduction
Diffuse gliomas are the most frequent primary malignant
cerebral tumors in adults. They are classified by the World
Health Organization (WHO) according to their phenotype
(astrocytic, oligodendrocytic and oligoastrocytic) and their
grade of malignancy (from WHO grades II to IV) [1, 2].
Anaplastic or WHO grade III oligodendroglial tumors
(AOTs), including anaplastic oligodendrogliomas and
anaplastic oligoastrocytomas, are particularly disconcerting
tumors: despite similar clinical, radiological and patho-
logical features, these tumors exhibit dramatically hetero-
geneous outcomes. The overall survival (OS) of AOT
patients varies from 2 to 10 years [3–6]. Moreover, the
diagnosis of AOTs suffers from a significant interobserver
variation that complicates the apprehension of these tumors
[7, 8].
Since the princeps studies conducted by Reifenberger
et al. and Cairncross et al., several independent teams have
validated that the chromosome arms 1p/19q codeletion is
frequent in AOTs and is a relevant genomic biomarker
associated with longer survival and better chemosensitivity
in AOTs [4, 5, 9–12]. Interestingly, this cytogenetic
imbalance has recently been linked to a chromosome
translocation (1;19) (q10;p10) and has been shown to be
mutually exclusive from high level gene amplification
[13–15]. Classically, in the subgroup of high grade glio-
mas, EGFR high level amplification is strongly associated
with WHO grade IV astrocytomas (glioblastomas or
GBMs) [16–19]. However, it is also observed in AOTs, and
its detection does not permit the conversion of a diagnosis
of an AOT into that of a GBM according to strictly mor-
phology-based WHO criteria [15, 20–23].
Taken together, these data suggest that the 1p/19q
codeleted AOTs form a very singular clinico-genetic sub-
group of AOTs: (1) distinct from their morphological non-
1p/19q codeleted counterparts in terms of chemosensitivity
and prognosis, and (2) genetically separated from EGFR-
amplified AOTs because these alterations are mutually
exclusive. The presence and the clinical significance of
EGFR amplification in AOTs are not definitively eluci-
dated but have been shown to be associated with poor
prognosis [21, 24].
Finally, the non-1p/19q codeleted and non-EGFR-
amplified AOTs remain a heterogeneous group of tumors
without specific recurrent genomic background. This
prompted us to conduct the present study using Bacterial
Artificial Chromosome (BAC)-array-based comparative
genomic hybridization (aCGH) analyzing the genomic pat-
terns of a series of 60 AOTs included in the EORTC trial
26951. The EORTC clinical trial 26951 was a prospective
randomized phase III study comparing radiotherapy plus
chemotherapy with procarbazine, lomustine and vincristine
(PCV) versus radiotherapy alone as first line treatment in a
cohort of 368 patients with AOTs [4]. This homogeneously-
treated patient population allows the determination of the
significance of the various genetic profiles of AOTs.
Materials and methods
Materials
Eligible for this study were all patients that were enrolled in
EORTC study 26951 and from whom frozen tumor material
was available for further research. Freezing tumor samples
was not mandatory in the design of the EORTC clinical trial
26951. However, high quality DNA extracted from frozen
tissue was required for running aCGH. Therefore, European
centers participating to the clinical trial and known to freeze
tumor tissue were contacted. Eligible for this clinical trial
were patients with anaplastic oligodendroglioma or oligo-
astrocytoma according to the WHO 1994 definition as
diagnosed by the local pathologist, with at least 3 out of 5
anaplastic characteristics (nuclear polymorphism, mitosis,
high cellularity, endothelial proliferation and necrosis). The
details of the study are described elsewhere [4]. For the
present analysis, the pathological diagnosis of the local and
the central pathologists were used. For the conduct of the
study and the present translational research study, approval
was obtained from national and local institutional review
boards according to national and local regulations; written
informed consent was obtained from all patients prior to
study entry.
BAC-array comparative genomic hybridization
Tumor DNA was successively extracted from frozen tumor
tissue using a commercial kit (QIAamp DNA mini Kit;
Qiagen, Courtaboeuf, France), digested with DpnII
(Ozyme, Saint Quentin en Yvelines, France), column-
purified (Qiaquick PCR purification kit; Qiagen) and
labeled by the random priming technique (Bioprime DNA
labelling system; Invitrogen, Cergy-Pontoise, France) with
cyanine-5 (Perkin-Elmer, Wellesley, MA, USA). The same
procedure was applied to control DNA with cyanine-3.
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Probes were cohybridized on the aCGH after the following
steps: (1) ethanol-coprecipitation with 140 lg of Human
Cot-1 DNA (Invitrogen), (2) resuspension in hybridization
buffer containing 50% of formamide, (3) heat-denaturation
at 95C during 10 min, and (4) prehybridization at 37C
for 90 min. Thirty-seven tumors were run on the aCGH
(Integragen, Paris, France) analyzing 4,500 sequence-val-
idated BACs and 13 tumors, part of a previous study, were
run on the previous version of the chip containing 3,342
BACs [15]. The 4,500 and the 3,342 BACs were spotted on
the array in quadruplicate and in triplicate, respectively.
Five hundred were cancer-related genes and the other
BACs were picked approximately across the genome of
each megabase. Arrays were washed and scanned using a
4000B scanner (Axon, Union City, CA, USA). Images
were analyzed with the Genepix6.0 software (AxonA).
Data were processed through the CAPweb platform to
obtain Cy5/Cy3 fluorescence ratios and status (gained, lost,
amplified or normal) for each BAC [25].
Fluorescent in situ hybridization (FISH) analysis
FISH experiments were conducted as previously reported
[26]. Briefly, probes to 1p36, centromere 1, 19p and 19q13
were D1S32, CEP1/pUC1.77, equivalent amounts of human
BACs RPCI-11 959O6/957I1/153P24 (BacPac Resources,
Oakland, CA, USA) and RPCI-11 426G3 (Research Genetics,
Huntsville, AL, USA) respectively. CEP1/pUC1.77, RPCI-11
959O6/957I1/153P24 were labeled with digoxigenin-16-
dUTP (Roche Diagnostics, Mannheim, Germany), D1S32
with biotin-16-dUTP (Roche Diagnostics, Mannheim, Ger-
many) and RPCI-11 426G3 with spectrum orange-dUTP
(Vysis, Downers Grove, IL, USA). Paired probes were
hybridized upon the pre-processed tumor section and detected
using anti-digoxigenin conjugated with fluorescein isothio-
cyanate (FITC; Roche Diagnostics) or CY3-conjugated avidin
(Brunschwig Chemie, Amsterdam, Netherlands) antibodies.
Nuclei were counterstained using DAPI mixed with an
antifade solution (Vector Laboratories, Burlingam, CA,
USA).
Statistical analysis
From the 3,301 BACs common to the two versions of the
aCGH, the BACs missing for more than 40 values (out of
60) were excluded. From the 3,115 remaining BACs, the
2,983 BACs located on the 22 autosomes were analyzed.
For the survival analysis, we considered a binary-tree
method because already known data can be incorporated
into the partition procedure, particularly the mutual
exclusion of chromosome arms 1p/19q codeletion, with
EGFR high level amplification distinguishing two singular
clear-cut genomic groups.
The binary-tree procedure selects cut points for pre-
dictors that best optimize the classical Cox proportional-
hazards regression score statistic. This latter statistic
measures the relationship between BAC status (deleted,
normal, gained) and time to event under the null
hypothesis. Here, the candidate predictors (for each
autosome short/long arms) were built from survival-rela-
ted BACs in a classical linear combination fashion. For
taking into account multiple-testing problem (numerous
BACs, numerous combination of BACs, numerous
tumors, numerous additional variables), we controlled
the local false discovery rate (probability of having
no association given the observed statistic) at a 15%
threshold. [27] As mentioned above, two special candi-
date predictors were constructed for EGFR high level
amplification and chromosome arms 1p/19q codeletion. In
practice, our tree was built according to the following
procedure:
1. From a univariate Cox proportional-hazards regres-
sion model, we identified BACs significantly associ-
ated with the OS. From the significant BACs on
chromosome 7 (containing EGFR locus), we calcu-
lated a score X which is a candidate predictor for the
chromosome 7 such that:
Xj ¼
P60
i¼1 xij  1lfdrðiÞ\0;15  1chrðiÞ¼7
P60
i¼1 1lfdrðiÞ\0;15  1chrðiÞ¼7
where xij is the status for the BAC i and for the patient
j, and lfdr(i) and and chr(i) are the estimated lfdr and
the chromosome number for the BAC i, respectively.
2. Adjusting the Cox proportional-hazards regression
model on X, we repeated the analysis excluding BACs
located on chromosome 7. From the significant BACs
on chromosome arms 1p and 19q, we calculated a
score Y giving the patient status according to 1p/19q
such that:
Yj ¼
P60
i¼1 xij  1lfdrðiÞ\0;15  1chrðiÞ201;19
P60
i¼1 1lfdrðiÞ\0;15  1chrðiÞ201;19
:
3. Adjusting the Cox proportional-hazards regression
model on both X and Y, we repeated the analysis
excluding BACs situated on chromosome 1 and 19.
From the new identified region on chromosome 21
(independent from EGFR and 1p/19q), we calculated
candidate predictor Z such that:
Zj ¼
P60
i¼1 xij  1lfdrðiÞ\0;15  1chrðiÞ¼21
P60
i¼1 1lfdrðiÞ\0;15  1chrðiÞ¼21
A classification rule was then defined according to the
three scores X, Y and Z. The cutoff values were determined
so that the classification rule gives a good balance between
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a sufficient number of patients in each group and a good
separation for the four groups. The survival curves
obtained from the Kaplan–Meier method were compared
using log-rank tests.
Finally, significant prognostic factors in univariate ana-
lyze were included as candidate variables in a multivariate
Cox proportional-hazards regression model analysis.
Association of genetic-prognostic patterns or groups
(revealed by the binary-tree method) with clinical, radio-
logical and pathological features of tumors was evaluated
using the v2 test. Continuous ages were compared using a
Mann–Whitney test. Agreement between aCGH and FISH
results were evaluated using Cohen’s kappa test. Statistical
tests were performed using XLSTAT software. A p value
\ 0.05 was considered as significant.
Results
Patients and tumors characteristics
Frozen material was available for 60 patients (from 4
different centers) out of the 368 patients enrolled in the
EORTC trial 26951. They were 34 men and 26 women (sex
ratio = 1.3). The median age of the patients at diagnosis was
48.0 years (range 19.2–67.6) WHO performance status was
0, 1 and 2 in 21, 25 and 14 cases respectively. Forty-three
tumors (71.7%) were diagnosed as anaplastic oligodendro-
glioma and 17 (29.3%) as anaplastic oligoastrocytomas.
The tumor location was frontal in 20 (33.3%) cases and
elsewhere in brain in 40 cases (66.7%). Radiological contrast
enhancement was seen in 34 cases (85.0%). In 7 cases
(11.7%), a previous resection of a low grade tumor had been
performed. With respect to treatments, a biopsy alone, a
partial resection and a complete resection were performed in
2 (3.3%), 34 (56.7%) and 24 (40.0%) patients, respectively.
After surgery, 29 patients (48.3%) were randomized to the
‘‘radiotherapy plus chemotherapy by PCV’’ arm, and 31
patients (51.7%) to the ‘‘radiation therapy alone’’ arm.
The characteristics of the patients and the tumors
included in the present study do not differ significantly
from those ones of the entire cohort of patients and tumors
included in the EORTC trial 26951, except for the surgical
procedure. Indeed, in the current cohort, 97% of patients
were treated with surgical resection (total and partial)
versus 86% in the entire cohort patients of the clinical trial
(p = 0.03) (Supplementary Table 1). Similarly, among the
patients and the tumors, with a centrally reviewed–
validated diagnosis of AOTs, those included in the present
study were very similar to those not included in the pres-
ent study except for the brain location. Indeed, in the
present study, 29% of the centrally reviewed–validated
AOTs were located in the frontal lobes versus 48% in the
cohort of tumors not included in the present study
(p = 0.03) (Supplementary Table 2).
Genomic abnormalities
Several recurrent genomic imbalances were observed in the
series. At a chromosome level, the most frequent chro-
mosome arm gain involved chromosome arms 7q, 7p, 10p,
10q, 19p in 51.7, 40.0, 28.3, 23.3 and 21.7% of cases,
respectively. The most frequently lost chromosome arms
were 10q, 10p, 9p, 19q, 22q, 1p, 14q and 13q in 50.0, 41.7,
38.3, 38.3, 31.7, 30.0, 23.3 and 21.7% of tumors, respec-
tively. At a BAC level, the most frequently gained and lost
BACs were located on chromosomes 7 and 10, respectively
(Fig. 1; Supplementary Tables 3 and 4). Interestingly,
several BACs containing genes of interest in gliomas such
as MGMT, CDKN2A, PTEN, EGFR and MET have been
found abnormal in more than 50.0% of tumors (Supple-
mentary Tables 3, 4).
FISH experiments testing chromosome arms 1p/19q and
EGFR status were conducted in 53/60 and 35/60 samples,
respectively. The agreement between FISH and aCGH for
Fig. 1 Frequencies of genomic
abnormalities in the entire
population of anaplastic
oligodendroglial tumors. The
x-axis indicates the BACs and
chromosome arms along the
genome while the y-axis
indicates the frequency of
genomic alterations with
genomic losses on the bottom
(gray histograms) and genomic
gains on top (black histograms)
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detection of 1p/19q codeletion and EGFR high level
amplification was good (kappa = 0.6 and 0.8, respectively)
(Supplementary Table 5).
BACs with prognostic value highlight four clinico-
genomic groups of anaplastic oligodendroglial tumors
(Figs. 2, 3, and 4)
Based on the analysis of the 2,983 BACs, the binary-tree
method identified 33/2,983 relevant BACs with prognostic
value located on chromosomes 1, 7 and 21. These 33 BACs
with prognostic value permit the building of four clinico-
genomic subgroups (Types I to IV) of AOTs (Fig. 2;
Supplementary Table 6). Chromosome locations of these
33 BACs with prognostic value are reported in Fig. 3.
Analysis based on both initial and centrally reviewed–
validated pathological diagnosis
Analysis was run both on initial diagnosis and on centrally
reviewed–validated pathological diagnosis. In the series of
the 60 AOTs at initial diagnosis, the clinico-pathological
characteristics of the entire cohort of patients and the four
genetic-prognostic subgroups are in Supplementary Table 7.
Interestingly, the univariate and multivariate analysis
showed that genomic group provides additional prognostic
information to the other variables, particularly age (Fig. 4a;
Supplementary Table 8).
Among the 60 AOTs, 45 were confirmed as AOTs (31
anaplastic oligodendrogliomas and 14 anaplastic oligoas-
trocytomas) by the central pathological reviewer [8]. The
excluded samples after central review were high grade
astrocytomas (62%) and low grade gliomas (38%). Among
the 45 tumors, the genomic types I, II, III and IV were
observed in 15, 9, 4 and 17 tumors, respectively. Clinical,
radiological and pathological characteristics of the reviewed
AOTs are reported in the Table 1.
Type I AOTs, with EGFR high level amplification, were
observed mainly in the elderly patients. All the type I
Fig. 2 Genetic-prognostic tree built from the 33 relevant genetic-
prognostic BACs
Fig. 3 Chromosome location of
the 33 BACs with prognostic
value identified as relevant to
build the genetic-prognostic tree
(see Supplementary Table 4 for
the full-length name and
genomic position of BACs
reported in this figure). a, b and
c indicate chromosomes 1, 7
and 21, respectively. Along the
vertical axis, each dot represents
a BAC. The horizontal axis
indicates chromosome distance
from the telomere (d) of BACs
with prognostic value identified
in each chromosome. Broken
arrow indicates chromosome
centromere
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tumors presented high cellularity, cytonuclear atypia and
endothelial abnormalities. In addition, type I AOTs
exhibited the higher rate of necrosis and were rarely
observed in the frontal brain lobes.
Type II tumors, with loss of the BACs with prognostic
value located on chromosome arm 1p (strongly associated
with chromosome arm 19q loss), were exclusively oligo-
dendrogliomas with mitosis and endothelial abnormalities.
The majority of type II tumors did not present any necrosis
and were located in the frontal regions.
Type III AOTs included a very small number of tumors
(n = 4). Type III AOTs patients were the youngest com-
pared to the patients from the other genomic type tumors.
None of the tumors were located in the frontal lobes and
only 2 of 4 tumors were contrast-enhanced on radiological
examination. The lowest rates of mitosis and endothelial
abnormalities were observed in this genomic subgroup.
Type IV tumors did not present either EGFR amplifi-
cation or loss of the BACs with prognostic value located on
chromosome arms 1p and 21q.
In the population of centrally confirmed AOTs, OS
remained significantly different between the four genomic
groups (p \ 0.001) (Fig. 4b). Age is also a strong prog-
nostic factor in the series of centrally reviewed–validated
AOTs. Patients with genomic type I tumor were signifi-
cantly older than patients with another genomic type
tumor. Multivariate analysis, including age and genomic
type (type I vs others or type I&III vs others), showed in
Fig. 4 Overall survival of anaplastic oligodendroglial tumors (AOT)
patients according to the genetic-prognostic type of their tumor based
on the initial diagnosis of AOT (a) and the centrally reviewed-
validated diagnosis of AOT (b). Kaplan–Meier curves with x-axis and
y-axis indicating the overall survival in years and the percentage of
survivors, respectively. Thick continuous line, thin continuous line,
thick broken line and thin broken line indicate type II, type IV, type
III and type I tumors patients, respectively
Table 1 Features of the
centrally reviewed alidated
anaplastic oligodendroglial
tumors: the entire population
and the four genomic subgroups
Entire
population
Type I Type II Type III Type IV
n 45 15 9 4 17
Sex ratio (male/female) 25/20 7/8 7/2 2/2 9/8
Age: median (years) 48.0 55.5 43.6 34.6 43.5
Age: range (years–years) 19.2–66.8 36.7–66.8 31.0–58.7 20.7–59.0 19.2–60.0
Oligodendroglioma/Oligoastrocytoma (%/%) 69/31 53/47 100/0 50/50 71/29
High cellularity (%) 93 100 89 100 88
Presence of cytonuclear atypia (%) 98 100 89 100 100
Mitosis (%) 89 93 100 75 82
Endothelial abnormalities (%) 96 100 100 75 94
Necrosis (%) 73 87 44 50 82
Frontal location (%) 29 13 78 0 24
Contrast enhancement (%) 84 87 78 75 88
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both situations (type I vs others or type I&III vs others) that
age and genomic type provide independent prognostic data
(p \ 0.0001). Therefore, difference in outcome, between
genomic types, is not exclusively attributable to the age
difference (Table 2).
Discussion
The diagnosis, the treatment and the prognosis prediction
of AOTs remain a clinical challenge particularly in the
non-1p/19q codeleted tumors [4, 5, 10]. In this latter
heterogeneous group, new specific predictors of outcome
and sensitivity to treatments are needed.
In a previous study on a series of gliomas of various
histologies, we have shown that the 1p/19q codeletion is
perfectly mutually exclusive from EGFR high level ampli-
fication [15]. These two genomic abnormalities allow
identification of two clear-cut homogeneous subgroups of
gliomas defined positively (EGFR-amplified vs 1p/19q
codeleted tumors). These molecular abnormalities observed
in 46.7% of the AOTs in the present series were used to build
the first branches of the genetic-prognostic tree. Then, the
statistical algorithm searched for additional biomarkers
Table 2 Univariate and multivariate analysis in the population of centrally reviewed–validated anaplastic oligodendroglial tumors
n Median
OS (years)
Univariate analysis Multivariate analysis
p value HR (95%CI) p value HR (95%CI)
Contrast enhancement
No 7 1.2
Yes 38 2.0
Type of surgery
Biopsy 2 1.2
Resection 43 2.0
Brain location
Frontal 13 NR 0.005 0.28 (0.17-0.73)
Non-frontal 32 1.6
Genomic type
II and IV 26 4.2 \0.0001 0.26 (0.07-0.37) 0.0006 4.4 (1.9-10.3)
I and III 19 1.2
Age
B 48.0 21 1.2 \0.0001 0.22 (0.08-0.37) 0.0002 4.6 (2.1-10.3)
[48.0 24 6.7
WHO performance status
0–1 35 3.0 0.003 3.48 (2.57-23.98)
2 10 1.0
Treatment
RT alone 23 1.4 0.01 0.43 (0.20-0.82)
RT ? PCV 22 4.2
Necrosis
No 12 3.0
Yes 33 1.6
Previous surgical resection for a lower grade glioma
No 42 1.6 0.04 NA
Yes 3 NR
Endothelial abnormalities
No 2 NR
Yes 43 1.6
Tumor type
Oligodendroglioma 31 2.5
Oligoastrocytoma 14 1.5
WHO World Health Organization, RT radiotherapy, PCV chemotherapy by procarbazine ? lomustine ? vincristione, NR not reached, NA not
available
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associated with OS in the non-1p/19q codeleted and non-
EGFR-amplified AOTs. Since this is a post-hoc exploratory
study, this needs confirmation in a second independent
dataset.
In agreement with previous reports, the 1p/19q code-
leted AOTs (type II) were anaplastic oligodendrogliomas
located in the frontal lobes and with long OS (median OS
not reached at 8 years) [4, 5, 10, 11, 28]. The present study
also confirmed the interest in testing the extent of the 1p36
deletion in gliomas to distinguish the whole 1p arm loss
versus focal 1p36 loss and the input of whole genomic
approaches [29–31].
AOTs with EGFR amplification (type I) exhibited a
higher rate of necrosis and were observed in older patients
with a short OS (median *1 year). These tumors share very
similar clinico-pathological features with GBMs (‘‘GBM-
like AOT’’). However, the WHO classification does not
include genomic data in gliomas diagnosis. The clinical
implications of EGFR amplification are not perfectly known
in AOTs, but this molecular abnormality seems to be asso-
ciated with unfavorable outcome [21, 24]. Similarly, the
EGFR amplification prevalence in AOTs is debatable,
varying from less than 10 to *40 probably due to differ-
ences in interpretation of histological criteria by pathologists
[17, 20, 23, 24, 32, 33]. In the present series, EGFR high
level amplification was seen in 25% of tumors which is in
agreement with the results obtained in a larger set of patients
taken from the clinical trial EORTC 26951 [4, 34]. Apart
from the evaluation of the 1p/19q status in AOT, assessing
the EGFR gene status in AOTs may help in understanding
the clinical outcome of these tumors, since they may actually
be better off with treatment as is given to GBM.
Fifty-three percent of tumors showed neither 1p/19q
codeletion nor EGFR high level amplification. Interest-
ingly, the binary tree method strategy used in the present
study identified chromosome 21q loss as an additional
biomarker in this group of AOTs. It is observed in *12%
of cases and associated with poor prognosis (median
OS = 1.6 years). To our knowledge, chromosome 21q loss
has never been reported as a genomic biomarker in AOTs.
In the lost BACs on chromosome 21 associated with
prognosis, OLIG2 is listed. OLIG2 is a transcription factor
expressed in oligodendroglial and at a lower level in
astrocytic gliomas [35, 36]. This leads us to speculate that
AOTs with a genomic loss of OLIG2 locus might have a
lower expression of OLIG2 and thus are closer to astrocytic
tumor whose prognosis is worse than their same grade
oligodendroglial counterpart [3]. Type IV AOTs is defined
negatively by the absence of the genomic abnormalities
seen in the other types of AOTs and includes a significant
number of tumors (42%). This highlights the complexity
and the heterogeneity of AOTs and supports additional
correlative studies including clinical, pathological and
molecular characteristics of patients and tumors in this
tumor group searching for other key markers.
Multivariate analysis revealed that genomic information
provides putatively interesting additional prognostic
information to clinical, radiological and pathological data.
Indeed, the two independent prognostic factors identified in
the present series were age and genomic pattern. In con-
trast, tumor phenotype, necrosis and contrast enhancement
were not independent prognostic factors in the present
series. Multivariate analysis was impossible in the series of
45 AOTs confirmed at review due to the small number of
tumors and the numerous prognostic factors identified in
the univariate analysis. In a larger series of patients from
the same trial, using FISH on paraffin-embedded tissue
samples, 1p/19q codeletion, phenotype and necrosis but not
EGFR amplification were found to be of prognostic value
[34]. The prognostic significance of these markers was also
checked in the series of 45 AOTs reviewed. The deletion of
the BACs located on chromosome arm 1p (tightly associ-
ated with the deletion of the chromosome arm 19q) had
also prognostic impact in the series of 45 AOTs reviewed
(p = 0.0042). However, EGFR amplification did have
prognostic value (p \ 0.0001) in this series, while neither
the presence of tumor necrosis nor the tumor phenotype
were associated with OS. These differences might be
explained by several reasons. The present series is much
smaller and therefore has limited power. Despite the good
agreement between aCGH and FISH techniques, we have
noticed a few discrepancies putatively due to interpretation
issues, technical limits and/or genomic tumor heterogene-
ity. These disagreements may explain some of the differ-
ences observed between the two studies. Finally, necrosis
and the diagnosis of an oligoastrocytic tumor are tightly
associated with EGFR high level amplification and could
summarize prognostic information provided by EGFR high
amplification in our study.
To our knowledge, the present study is the first dedi-
cated to clinico-genomic correlations specifically in the
group of AOTs using BAC-array CGH and a binary tree
approach. It is noteworthy that the present and the entire
population of the EORTC 26951 trial are very similar in
terms of 1p/19q status and pathology.
Several studies conducted in gliomas have shown the
feasibility and the interest of array CGH for identification
of relevant copy number abnormalities and candidate bio-
markers [15, 22, 30, 37–45].
Kitange et al. and Trost et al. have identified the chro-
mosome 8q gain as a biomarker of worse prognosis in
series of 35 oligodendroglial tumors and 49 anaplastic ol-
igodendrogliomas, respectively [46, 47]. The prevalence of
chromosome 8q gain in the present series (23%) is similar
to the one reported by Kitange et al. However, we did not
see any prognostic value of chromosome 8q in our series
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(p = 0.2) which included exclusively WHO grade III
tumors in contrast to Kitange’s series which included both
grade II and III tumors. In an independent set of anaplastic
oligodendroglioma,s we recently showed that high level
gene amplification, whatever the gene involved, is associ-
ated with a poor prognosis [48].
More recently, Giannini et al. have reported a transla-
tional study investigating prognostic factors, including the
chromosome arms 1p/19q status assessed by FISH, in AOTs
from the Trial 9402 conducted by the Radiation Therapy
Oncology Group [6]. Interestingly, they showed that path-
ological and molecular are synergistic, providing comple-
mentary prognosis information. Indeed, the histo-molecular
signature ‘‘1p/19q codeleted plus classic morphology’’ was
reported to the best predictor of better outcome in AOTs [6].
To conclude, AOTs are still a very heterogeneous group
of tumors with different outcome and genomic background.
The 1p/19q codeletion is a favorable prognostic marker and
is currently used as an eligibility criterion for trials on
anaplastic gliomas (EORTC 26053). Based on our results
and other studies, there is growing evidence that additional
prognostic markers are emerging particularly in the non-
1p/19q codeleted AOTs, such as necrosis, oligoastrocy-
toma phenotype, classic oligodendroglioma morphology,
gene amplification, 8q gain and 21q loss although they
need additional validating studies in independent datasets.
New generations of genomic arrays, single nucleotide
polymorphisms-based or oligonucleotides-based, more re-
solutive than aCGH and feasible, at least for some of them,
with different kinds of tissue (i.e. frozen or fixed), have
been implemented quite recently in different laboratories.
These tools will be extremely important to dissect in-depth
genomic profiles of AOTs and, through clinico-molecular
correlations, to identify new biomarkers in this group of
glial tumors [49–51].
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